A novel MEK1/2 inhibitor induces G1/S cell cycle arrest in human fibrosarcoma cells

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• The Extracellular signal-Regulated Kinase (ERK) pathway is a key regulator of cell proliferation and survival.
• Constitutive activation of the ERK pathway is implicated in the development of various cancers, including fibrosarcoma.
• Targeting the ERK pathway presents a potential therapeutic strategy for malignant tumors.

Purpose of the Study:

• To evaluate the antitumor activity of JTP-70902, a novel MEK inhibitor, against human fibrosarcoma cells.
• To investigate the effects of JTP-70902 on cell growth, cell cycle progression, and key signaling molecules in the ERK pathway.
• To assess the potential of JTP-70902 as a molecular-targeting therapeutic agent.

Main Methods:

• Human fibrosarcoma HT1080 cells were treated with varying concentrations of JTP-70902.
• Cell viability was assessed using the trypan blue dye exclusion test.
• Cell cycle analysis was performed using propidium iodide staining and flow cytometry (FACSCalibur).
• Western blot analysis was employed to examine protein expression and phosphorylation levels.

Main Results:

• JTP-70902 demonstrated dose-dependent inhibition of HT1080 cell growth, with complete inhibition at 200 nM.
• Flow cytometry analysis revealed JTP-70902 induced G1/S phase cell cycle arrest in a dose-dependent manner.
• JTP-70902 effectively inhibited ERK phosphorylation and decreased RB phosphorylation, while increasing p21WAF1/CIP1 and p27KIP1 protein expression.

Conclusions:

• JTP-70902 exhibits significant antitumor activity against human Ras mutant fibrosarcoma cells.
• The compound induces cell growth inhibition and cell cycle arrest, likely through modulation of the Ras-MEK-ERK pathway.
• JTP-70902 represents a promising candidate for molecular-targeting chemotherapy in soft tissue tumors with activated Ras-MEK-ERK signaling.